SBRT on Oligoprogressive Lesions: Benefit in Lung Cancer
Stereotactic body radiation therapy (SBRT) significantly improved progression-free survival in oligoprogressive, metastatic lung cancer, but not breast cancer.
Source: medscape.com
Page 2 - Response Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Response Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Response Evaluation Today - Breaking & Trending Today
COVID-19 First Wave Declined Liver Cancer Care
COVID-19 First Wave Declined Liver Cancer Care by Angela Mohan on February 9, 2021 at 3:15 PM Liver cancer care has been drastically reduced in the view of first wave of COVID-19. The delays of screening programmes, diagnostic imaging and biopsies, cuts in the numbers of physicians available to treat liver cancer patients, cancellations of surgery, and a drop in the number of patients entered on clinical trials, were just some of the issues reported in the poll. The global Liver Cancer Outcomes in COVID-19 (CERO-19) Survey led by the Barcelona Clinic Liver Cancer (BCLC) gr...
Source: medindia.net
U.S. Food and Drug Administration Approves OPDIVO® in Combination with CABOMETYX® as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
1 1,2 as a standard of care for intermediate- or poor-risk patients 3 OPDIVO ® (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX ® (cabozantinib) 40 mg once daily tablets was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). 1 The approval is based on the Phase 3 CheckMate -9ER trial, which compared OPDIVO in combination with CABOMETYX (n=323) versus sunitinib (n=328) in patients with advanced RCC. 1 Thi...
Source: investingnews.com